Restoring blood coagulation in patients
taking Factor Xa Direct Oral Anticoagulants
(FXa-DOACs)
Our focus lies in the development of a breakthrough, swift-acting, and convenient universal bypassing agent that restores blood coagulation in patients taking Factor Xa Direct Oral Anticoagulants (FXa-DOACs).
We aim to stop severe bleeding and eliminate bleeding risk during surgery in patients taking FXa DOACs.
VMX-C001: Transforming the treatment of bleeding in patients taking Factor Xa DOACs
News & events
- News
Enables initiation of global EquilibriX-S trial later this year Critical milestone in development of novel bypass agent to restore coagulation,...
- Management TeamNews